Helicobacter pylori

Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, microaerophilic, spiral (helical) bacterium usually found in the stomach. Its helical shape (from which the genus name, helicobacter, derives) is thought to have evolved in order to penetrate the mucoid lining of the stomach and thereby establish infection. The bacterium was first identified in 1982 by Australian doctors Barry Marshall and Robin Warren. "H. pylori" has been associated with lymphomas of the mucosa-associated lymphoid tissue in the stomach, esophagus, colon, rectum, or tissues around the eye (termed extranodal marginal zone B-cell lymphoma of the cited organ), and of lymphoid tissue in the stomach (termed diffuse large B-cell lymphoma).
"H. pylori" infection usually has no symptoms but sometimes causes gastritis (stomach inflammation) or ulcers of the stomach or first part of the small intestine. The infection is also associated with the development of certain cancers occurring in less than 20% of cases. Many investigators have suggested that "H. pylori" causes a wide range of other diseases (e.g. idiopathic thrombocytopenic purpura, iron deficiency anemia, atherosclerosis, Alzheimer's disease, multiple sclerosis, coronary artery disease, periodontitis, Parkinson's disease, Guillain–Barré syndrome, rosacea, psoriasis, chronic urticaria, spot baldness, various autoimmune skin diseases, Henoch–Schönlein purpura, low blood levels of , autoimmune neutropenia, the antiphospholipid syndrome, plasma cell dyscrasias, reactive arthritis, central serous chorioretinitis, open angle glaucoma, blepharitis, diabetes mellitus, the metabolic syndrome, various types of allergies, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatic fibrosis, and liver cancer). The bacterial infection has also been proposed to have protective effects for its hosts against infections by other pathogens, asthma, obesity, celiac disease, inflammatory bowel disease, rhinitis, atopic dermatitis, gastroesophageal reflux disease, and esophageal cancer. However, these deleterious and protective effects have frequently been based on correlative rather than direct relationship studies and have often been contradicted by other studies that show either the opposite or no effect on the cited disease. Therefore, many of these relationships remain controversial.
Some studies suggest that "H. pylori" plays an important role in the natural stomach ecology, e.g. by influencing the type of bacteria that colonize the gastrointestinal tract. Other studies suggest that non-pathogenic strains of "H. pylori" may beneficially normalize stomach acid secretion, and regulate appetite.
In 2015, it was estimated that over 50% of the world's population had "H. pylori" in their upper gastrointestinal tracts with this infection (or colonization) being more common in developing countries. In recent decades, however, the prevalence of "H. pylori" colonization of the gastrointestinal tract has declined in many countries. 
Signs and symptoms.
Up to 90% of people infected with "H. pylori" never experience symptoms or complications. However, individuals infected with "H. pylori" have a 10% to 20% lifetime risk of developing peptic ulcers. Acute infection may appear as an acute gastritis with abdominal pain (stomach ache) or nausea. Where this develops into chronic gastritis, the symptoms, if present, are often those of non-ulcer dyspepsia: Stomach pains, nausea, bloating, belching, and sometimes vomiting. Pain typically occurs when the stomach is empty, between meals, and in the early morning hours, but it can also occur at other times. Less common ulcer symptoms include nausea, vomiting, and loss of appetite.
Bleeding in the stomach can also occur as evidenced by the passage of black stools; prolonged bleeding may cause anemia leading to weakness and fatigue. If bleeding is heavy, hematemesis, hematochezia, or melena may occur. Inflammation of the pyloric antrum, which connects the stomach to the duodenum, is more likely to lead to duodenal ulcers, while inflammation of the corpus (i.e. body of the stomach) is more likely to lead to gastric ulcers. Individuals infected with "H. pylori" may also develop colorectal or gastric polyps, i.e. non-cancerous growths of tissue projecting from the mucous membranes of these organs. Usually, these polyps are asymptomatic but gastric polyps may be the cause of dyspepsia, heartburn, bleeding from the upper gastrointestinal tract, and, rarely, gastric outlet obstruction while colorectal polyps may be the cause of rectal bleeding, anemia, constipation, diarrhea, weight loss, and abdominal pain.
Individuals with chronic "H. pylori" infection have an increased risk of acquiring a cancer that is directly related to this infection. These cancers are stomach adenocarcinoma, less commonly diffuse large B-cell lymphoma of the stomach, or extranodal marginal zone B-cell lymphomas of the stomach, or, more rarely, of the colon, rectum, esophagus, or ocular adenexa (i.e. orbit, conjunctiva, and/or eyelids). The signs, symptoms, pathophysiology, and diagnoses of these cancers are given in the cited linkages.
Microbiology.
Morphology.
"Helicobacter pylori" is a helix-shaped (classified as a curved rod, not spirochaete) Gram-negative bacterium about 3 μm long with a diameter of about 0.5 μm . "H. pylori" can be demonstrated in tissue by Gram stain, Giemsa stain, haematoxylin–eosin stain, Warthin–Starry silver stain, acridine orange stain, and phase-contrast microscopy. It is capable of forming biofilms and can convert from spiral to a possibly viable but nonculturable coccoid form.
"Helicobacter pylori" has four to six flagella at the same location; all gastric and enterohepatic "Helicobacter" species are highly motile owing to flagella. The characteristic sheathed flagellar filaments of "Helicobacter" are composed of two copolymerized flagellins, FlaA and FlaB.
Physiology.
"Helicobacter pylori" is microaerophilic – that is, it requires oxygen, but at lower concentration than in the atmosphere. It contains a hydrogenase that can produce energy by oxidizing molecular hydrogen (H2) made by intestinal bacteria. It produces oxidase, catalase, and urease.
"H. pylori" possesses five major outer membrane protein families. The largest family includes known and putative adhesins. The other four families are porins, iron transporters, flagellum-associated proteins, and proteins of unknown function. Like other typical Gram-negative bacteria, the outer membrane of "H. pylori" consists of phospholipids and lipopolysaccharide (LPS). The O antigen of LPS may be fucosylated and mimic Lewis blood group antigens found on the gastric epithelium. The outer membrane also contains cholesterol glucosides, which are present in few other bacteria.
Genome.
"Helicobacter pylori" consists of a large diversity of strains, and hundreds of genomes have been completely sequenced. The genome of the strain "26695" consists of about 1.7 million base pairs, with some 1,576 genes. The pan-genome, that is a combined set of 30 sequenced strains, encodes 2,239 protein families (orthologous groups, OGs). Among them, 1,248 OGs are conserved in all the 30 strains, and represent the "universal core". The remaining 991 OGs correspond to the "accessory genome" in which 277 OGs are unique (i.e., OGs present in only one strain).
Transcriptome.
In 2010, Sharma "et al". presented a comprehensive analysis of transcription at single-nucleotide resolution by differential RNA-seq that confirmed the known acid induction of major virulence loci, such as the urease (ure) operon or the cag pathogenicity island (see below). More importantly, this study identified a total of 1,907 transcriptional start sites, 337 primary operons, and 126 additional suboperons, and 66 monocistrons. Until 2010, only about 55 transcriptional start sites (TSSs) were known in this species. Notably, 27% of the primary TSSs are also antisense TSSs, indicating that – similar to "E. coli" – antisense transcription occurs across the entire "H. pylori" genome. At least one antisense TSS is associated with about 46% of all open reading frames, including many housekeeping genes. Most (about 50%) of the 5′ UTRs are 20–40 nucleotides (nt) in length and support the AAGGag motif located about 6 nt (median distance) upstream of start codons as the consensus Shine–Dalgarno sequence in "H. pylori".
Genes involved in virulence and pathogenesis.
Study of the "H. pylori" genome is centered on attempts to understand pathogenesis, the ability of this organism to cause disease. About 29% of the loci have a colonization defect when mutated. Two of sequenced strains have an around 40 kb-long Cag pathogenicity island (a common gene sequence believed responsible for pathogenesis) that contains over 40 genes. This pathogenicity island is usually absent from "H. pylori" strains isolated from humans who are carriers of "H. pylori", but remain asymptomatic.
The "cagA" gene codes for one of the major "H. pylori" virulence proteins. Bacterial strains with the "cagA" gene are associated with an ability to cause ulcers. The "cagA" gene codes for a relatively long (1186-amino acid) protein. The "cag" pathogenicity island (PAI) has about 30 genes, part of which code for a complex type IV secretion system. The low GC-content of the "cag" PAI relative to the rest of the "Helicobacter" genome suggests the island was acquired by horizontal transfer from another bacterial species. The serine protease HtrA also plays a major role in the pathogenesis of "H. pylori". The HtrA protein enables the bacterium to transmigrate across the host cells' epithelium, and is also needed for the translocation of CagA.
The "vacA" () gene codes for another major "H. pylori" virulence protein. There are four main subtypes of "vacA": "s1/m1, s1/m2, s2/m1," and "s2/m2". "s1/m1" and "s1/m2" subtypes are known to cause increased risk of gastric cancer. This has been linked to the ability for toxigenic "vacA" to promote the generation of intracellular reservoirs of "H. pylori" via disruption of calcium channel TRPML1.
Pathophysiology.
Adaptation to the stomach.
To avoid the acidic environment of the interior of the stomach (lumen), "H. pylori" uses its flagella to burrow into the mucus lining of the stomach to reach the epithelial cells underneath, where it is less acidic. "H. pylori" is able to sense the pH gradient in the mucus and move towards the less acidic region (chemotaxis). This also keeps the bacteria from being swept away into the lumen with the bacteria's mucus environment, which is constantly moving from its site of creation at the epithelium to its dissolution at the lumen interface.
"H. pylori" is found in the mucus, on the inner surface of the epithelium, and occasionally inside the epithelial cells themselves. It adheres to the epithelial cells by producing adhesins, which bind to lipids and carbohydrates in the epithelial cell membrane. One such adhesin, BabA, binds to the Lewis b antigen displayed on the surface of stomach epithelial cells. "H. pylori" adherence via BabA is acid sensitive and can be fully reversed by decreased pH. It has been proposed that BabA's acid responsiveness enables adherence while also allowing an effective escape from unfavorable environment at pH that is harmful to the organism. Another such adhesin, SabA, binds to increased levels of sialyl-Lewis x antigen expressed on gastric mucosa.
In addition to using chemotaxis to avoid areas of low pH, "H. pylori" also neutralizes the acid in its environment by producing large amounts of urease, which breaks down the urea present in the stomach to carbon dioxide and ammonia. These react with the strong acids in the environment to produce a neutralized area around "H. pylori". Urease knockout mutants are incapable of colonization. In fact, urease expression is not only required for establishing initial colonization but also for maintaining chronic infection.
Adaptation of "H. pylori" to high acidity of stomach.
As mentioned above, "H. pylori" produce large amounts of urease to produce ammonia as one of its adaptation methods to overcome stomach acidity. Helicobacter pylori arginase, a bimetallic enzyme binuclear Mn2-metalloenzyme arginase, crucial for pathogenesis of the bacterium in human stomach, a member of the ureohydrolase family, catalyzes the conversion of L-arginine to L-ornithine and urea, where ornithine is further converted into polyamines, which are essential for various critical metabolic processes.
This provides acid resistance and is thus important for colonization of the bacterium in the gastric epithelial cells. Arginase of "H. pylori" also plays a role in evasion of the pathogen from the host immune system mainly by various proposed mechanisms, arginase competes with host-inducible nitric oxide (NO) synthase for the common substrate L-arginine, and thus reduces the synthesis of NO, an important component of innate immunity and an effective antimicrobial agent that is able to kill the invading pathogens directly.
Alterations in the availability of L-arginine and its metabolism into polyamines contribute significantly to the dysregulation of the host immune response to "H. pylori" infection.
Inflammation, gastritis and ulcer.
"Helicobacter pylori" harms the stomach and duodenal linings by several mechanisms. The ammonia produced to regulate pH is toxic to epithelial cells, as are biochemicals produced by "H. pylori" such as proteases, vacuolating cytotoxin A (VacA) (this damages epithelial cells, disrupts tight junctions and causes apoptosis), and certain phospholipases. Cytotoxin associated gene "CagA" can also cause inflammation and is potentially a carcinogen.
Colonization of the stomach by "H. pylori" can result in chronic gastritis, an inflammation of the stomach lining, at the site of infection. "Helicobacter" cysteine-rich proteins (Hcp), particularly HcpA (hp0211), are known to trigger an immune response, causing inflammation. "H. pylori" has been shown to increase the levels of COX2 in "H. pylori" positive gastritis.
Chronic gastritis is likely to underlie "H. pylori"-related diseases.
Ulcers in the stomach and duodenum result when the consequences of inflammation allow stomach acid and the digestive enzyme pepsin to overwhelm the mechanisms that protect the stomach and duodenal mucous membranes. The location of colonization of "H. pylori", which affects the location of the ulcer, depends on the acidity of the stomach.
In people producing large amounts of acid, "H. pylori" colonizes near the pyloric antrum (exit to the duodenum) to avoid the acid-secreting parietal cells at the fundus (near the entrance to the stomach). In people producing normal or reduced amounts of acid, "H. pylori" can also colonize the rest of the stomach.
The inflammatory response caused by bacteria colonizing near the pyloric antrum induces G cells in the antrum to secrete the hormone gastrin, which travels through the bloodstream to parietal cells in the fundus. Gastrin stimulates the parietal cells to secrete more acid into the stomach lumen, and over time increases the number of parietal cells, as well. The increased acid load damages the duodenum, which may eventually result in ulcers forming in the duodenum.
When "H. pylori" colonizes other areas of the stomach, the inflammatory response can result in atrophy of the stomach lining and eventually ulcers in the stomach. This also may increase the risk of stomach cancer.
"Cag" pathogenicity island.
The pathogenicity of "H. pylori" may be increased by genes of the "cag" pathogenicity island; about 50–70% of "H. pylori" strains in Western countries carry it, but it's virtually absent in East Asian strains. Western people infected with strains carrying the "cag" PAI have a stronger inflammatory response in the stomach and are at a greater risk of developing peptic ulcers or stomach cancer than those infected with strains lacking the island. Following attachment of "H. pylori" to stomach epithelial cells, the type IV secretion system expressed by the "cag" PAI "injects" the inflammation-inducing agent, peptidoglycan, from their own cell walls into the epithelial cells. The injected peptidoglycan is recognized by the cytoplasmic pattern recognition receptor (immune sensor) Nod1, which then stimulates expression of cytokines that promote inflammation.
The type-IV secretion apparatus also injects the "cag" PAI-encoded protein CagA into the stomach's epithelial cells, where it disrupts the cytoskeleton, adherence to adjacent cells, intracellular signaling, cell polarity, and other cellular activities. Once inside the cell, the CagA protein is phosphorylated on tyrosine residues by a host cell membrane-associated tyrosine kinase (TK). CagA then allosterically activates protein tyrosine phosphatase/protooncogene Shp2. Pathogenic strains of "H. pylori" have been shown to activate the epidermal growth factor receptor (EGFR), a membrane protein with a TK domain. Activation of the EGFR by "H. pylori" is associated with altered signal transduction and gene expression in host epithelial cells that may contribute to pathogenesis. A C-terminal region of the CagA protein (amino acids 873–1002) has also been suggested to be able to regulate host cell gene transcription, independent of protein tyrosine phosphorylation. A great deal of diversity exists between strains of "H. pylori", and the strain that infects a person can predict the outcome.
Cancer.
Two related mechanisms by which "H. pylori" could promote cancer are under investigation. One mechanism involves the enhanced production of free radicals near "H. pylori" and an increased rate of host cell mutation. The other proposed mechanism has been called a "perigenetic pathway", and involves enhancement of the transformed host cell phenotype by means of alterations in cell proteins, such as adhesion proteins. "H. pylori" has been proposed to induce inflammation and locally high levels of TNF-α and/or interleukin 6 (IL-6). According to the proposed perigenetic mechanism, inflammation-associated signaling molecules, such as TNF-α, can alter gastric epithelial cell adhesion and lead to the dispersion and migration of mutated epithelial cells without the need for additional mutations in tumor suppressor genes, such as genes that code for cell adhesion proteins.
The strain of "H. pylori" a person is exposed to may influence the risk of developing gastric cancer. Strains of "H. pylori" that produce high levels of two proteins, vacuolating toxin A (VacA) and the cytotoxin-associated gene A (CagA), appear to cause greater tissue damage than those that produce lower levels or that lack those genes completely. These proteins are directly toxic to cells lining the stomach and signal strongly to the immune system that an invasion is under way. As a result of the bacterial presence, neutrophils and macrophages set up residence in the tissue to fight the bacteria assault.
"H. pylori" is a major source of worldwide cancer mortality. Although the data varies between different countries, overall about 1% to 3% of people infected with "Helicobacter pylori" develop gastric cancer in their lifetime compared to 0.13% of individuals who have had no "H. pylori" infection. "H. pylori" infection is very prevalent. As evaluated in 2002, it is present in the gastric tissues of 74% of middle-aged adults in developing countries and 58% in developed countries. Since 1% to 3% of infected individuals are likely to develop gastric cancer, "H. pylori"-induced gastric cancer is the third highest cause of worldwide cancer mortality as of 2018.
Infection by "H. pylori" causes no symptoms in about 80% of those infected. About 75% of individuals infected with "H. pylori" develop gastritis. Thus, the usual consequence of "H. pylori" infection is chronic asymptomatic gastritis. Because of the usual lack of symptoms, when gastric cancer is finally diagnosed it is often fairly advanced. More than half of gastric cancer patients have lymph node metastasis when they are initially diagnosed.
The gastritis caused by "H. pylori" is accompanied by inflammation, characterized by infiltration of neutrophils and macrophages to the gastric epithelium, which favors the accumulation of pro-inflammatory cytokines and reactive oxygen species/reactive nitrogen species (ROS/RNS). The substantial presence of ROS/RNS causes DNA damage including 8-oxo-2'-deoxyguanosine (8-OHdG). If the infecting "H. pylori" carry the cytotoxic cagA gene (present in about 60% of Western isolates and a higher percentage of Asian isolates), they can increase the level of 8-OHdG in gastric cells by 8-fold, while if the "H. pylori" do not carry the cagA gene, the increase in 8-OHdG is about 4-fold. In addition to the oxidative DNA damage 8-OHdG, "H. pylori" infection causes other characteristic DNA damages including DNA double-strand breaks.
"H. pylori" also causes many epigenetic alterations linked to cancer development. These epigenetic alterations are due to "H. pylori"-induced methylation of CpG sites in promoters of genes and "H. pylori"-induced altered expression of multiple microRNAs.
As reviewed by Santos and Ribeiro "H. pylori" infection is associated with epigenetically reduced efficiency of the DNA repair machinery, which favors the accumulation of mutations and genomic instability as well as gastric carcinogenesis. In particular, Raza et al. showed that expression of two DNA repair proteins, ERCC1 and PMS2, was severely reduced once "H. pylori" infection had progressed to cause dyspepsia. Dyspepsia occurs in about 20% of infected individuals. In addition, as reviewed by Raza "et al"., human gastric infection with "H. pylori" causes epigenetically reduced protein expression of DNA repair proteins MLH1, MGMT and MRE11. Reduced DNA repair in the presence of increased DNA damage increases carcinogenic mutations and is likely a significant cause of "H. pylori" carcinogenesis.
Survival of "Helicobacter pylori".
The pathogenesis of "H. pylori" depends on its ability to survive in the harsh gastric environment characterized by acidity, peristalsis, and attack by phagocytes accompanied by release of reactive oxygen species. In particular, "H. pylori" elicits an oxidative stress response during host colonization. This oxidative stress response induces potentially lethal and mutagenic oxidative DNA adducts in the "H. pylori" genome.
Vulnerability to oxidative stress and oxidative DNA damage occurs commonly in many studied bacterial pathogens, including "Neisseria gonorrhoeae, Hemophilus influenzae, Streptococcus pneumoniae, S. mutans", and "H. pylori". For each of these pathogens, surviving the DNA damage induced by oxidative stress appears supported by transformation-mediated recombinational repair. Thus, transformation and recombinational repair appear to contribute to successful infection.
Transformation (the transfer of DNA from one bacterial cell to another through the intervening medium) appears to be part of an adaptation for DNA repair. "H. pylori" is naturally competent for transformation. While many organisms are competent only under certain environmental conditions, such as starvation, "H. pylori" is competent throughout logarithmic growth. All organisms encode genetic programs for response to stressful conditions including those that cause DNA damage. In "H. pylori", homologous recombination is required for repairing DNA double-strand breaks (DSBs). The AddAB helicase-nuclease complex resects DSBs and loads RecA onto single-strand DNA (ssDNA), which then mediates strand exchange, leading to homologous recombination and repair. The requirement of RecA plus AddAB for efficient gastric colonization suggests, in the stomach, "H. pylori" is either exposed to double-strand DNA damage that must be repaired or requires some other recombination-mediated event. In particular, natural transformation is increased by DNA damage in "H. pylori", and a connection exists between the DNA damage response and DNA uptake in "H. pylori", suggesting natural competence contributes to persistence of "H. pylori" in its human host and explains the retention of competence in most clinical isolates.
RuvC protein is essential to the process of recombinational repair, since it resolves intermediates in this process termed Holliday junctions. "H. pylori" mutants that are defective in RuvC have increased sensitivity to DNA-damaging agents and to oxidative stress, exhibit reduced survival within macrophages, and are unable to establish successful infection in a mouse model. Similarly, RecN protein plays an important role in DSB repair in "H. pylori". An "H. pylori" recN mutant displays an attenuated ability to colonize mouse stomachs, highlighting the importance of recombinational DNA repair in survival of "H. pylori" within its host.
Diagnosis.
Colonization with "H. pylori" is not a disease in and of itself, but a condition associated with a number of disorders of the upper gastrointestinal tract. Testing for "H. pylori" is not routinely recommended. Testing is recommended if peptic ulcer disease or low-grade gastric MALT lymphoma (MALToma) is present, after endoscopic resection of early gastric cancer, for first-degree relatives with gastric cancer, and in certain cases of dyspepsia. Several methods of testing exist, including invasive and noninvasive testing methods.
Noninvasive tests for "H. pylori" infection may be suitable and include blood antibody tests, stool antigen tests, or the carbon urea breath test (in which the patient drinks 14C – or 13C-labelled urea, which the bacterium metabolizes, producing labelled carbon dioxide that can be detected in the breath). It is not known which non-invasive test is more accurate for diagnosing a "H. pylori" infection, and the clinical significance of the levels obtained with these tests is not clear.
An endoscopic biopsy is an invasive means to test for "H. pylori" infection. Low-level infections can be missed by biopsy, so multiple samples are recommended. The most accurate method for detecting "H. pylori" infection is with a histological examination from two sites after endoscopic biopsy, combined with either a rapid urease test or microbial culture.
Transmission.
"Helicobacter pylori" is contagious, although the exact route of transmission is not known.
Person-to-person transmission by either the oral–oral or fecal–oral route is most likely. Consistent with these transmission routes, the bacteria have been isolated from feces, saliva, and dental plaque of some infected people. Findings suggest "H. pylori" is more easily transmitted by gastric mucus than saliva. Transmission occurs mainly within families in developed nations, yet can also be acquired from the community in developing countries. "H. pylori" may also be transmitted orally by means of fecal matter through the ingestion of waste-tainted water, so a hygienic environment could help decrease the risk of "H. pylori" infection.
Prevention.
Due to "H. pylori"’s role as a major cause of certain diseases (particularly cancers) and its consistently increasing antibiotic resistance, there is a clear need for new therapeutic strategies to prevent or remove the bacterium from colonizing humans. Much work has been done on developing viable vaccines aimed at providing an alternative strategy to control "H. pylori" infection and related diseases. Researchers are studying different adjuvants, antigens, and routes of immunization to ascertain the most appropriate system of immune protection; however, most of the research only recently moved from animal to human trials. An economic evaluation of the use of a potential "H. pylori" vaccine in babies found its introduction could, at least in the Netherlands, prove cost-effective for the prevention of peptic ulcer and stomach adenocarcinoma. A similar approach has also been studied for the United States. Notwithstanding this proof-of-concept (i.e. vaccination protects children from acquisition of infection with "H. pylori"), as of late 2019 there have been no advanced vaccine candidates and only one vaccine in a Phase I clinical trial. Furthermore, development of a vaccine against "H. pylori" has not been a current priority of major pharmaceutical companies.
Many investigations have attempted to prevent the development of "Helicobacter pylori"-related diseases by eradicating the bacterium during the early stages of its infestation using antibiotic-based drug regimens. Studies find that such treatments, when effectively eradicating "H. pylori" from the stomach, reduce the inflammation and some of the histopathological abnormalities associated with the infestation. However studies disagree on the ability of these treatments to alleviate the more serious histopathological abnormalities in "H. pylori" infections, e.g. gastric atrophy and metaplasia, both of which are precursors to gastric adenocarcinoma. There is similar disagreement on the ability of antibiotic-based regiments to prevent gastric adenocarcinoma. A meta-analysis (i.e. a statistical analysis that combines the results of multiple randomized controlled trials) published in 2014 found that these regimens did not appear to prevent development of this adenocarcinoma. However, two subsequent prospective cohort studies conducted on high-risk individuals in China and Taiwan found that eradication of the bacterium produced a significant decrease in the number of individuals developing the disease. These results agreed with a retrospective cohort study done in Japan and published in 2016 as well as a meta-analysis, also published in 2016, of 24 studies conducted on individuals with varying levels of risk for developing the disease. These more recent studies suggest that the eradication of "H. pylori" infection reduces the incidence of "H. pylori"-related gastric adenocarcinoma in individuals at all levels of baseline risk. Further studies will be required to clarify this issue. In all events, studies agree that antibiotic-based regimens effectively reduce the occurrence of metachronous "H. pylori"-associated gastric adenocarcinoma. (Metachronous cancers are cancers that reoccur 6 months or later after resection of the original cancer.) It is suggested that antibiotic-based drug regimens be used after resecting "H. pylori"-associated gastric adenocarcinoma in order to reduce its metachronus reoccurrence.
Treatment.
Gastritis.
Superficial gastritis, either acute or chronic, is the most common manifestation of "H. pylori" infection. The signs and symptoms of this gastritis have been found to remit spontaneously in many individuals without resorting to "Helicobacter pylori" eradication protocols. The "H. pylori" bacterial infection persists after remission in these cases. Various antibiotic plus proton pump inhibitor drug regimens are used to eradicate the bacterium and thereby successfully treat the disorder with triple-drug therapy consisting of clarithromycin, amoxicillin, and a proton-pump inhibitor given for 14–21 days often being considered first line treatment.
Peptic ulcers.
Once "H. pylori" is detected in a person with a peptic ulcer, the normal procedure is to eradicate it and allow the ulcer to heal. The standard first-line therapy is a one-week "triple therapy" consisting of proton-pump inhibitors such as omeprazole and the antibiotics clarithromycin and amoxicillin. (The actions of proton pump inhibitors against H. pylori may reflect their direct bacteriostatic effect due to inhibition of the bacterium's P-type ATPase and/or urease.) Variations of the triple therapy have been developed over the years, such as using a different proton pump inhibitor, as with pantoprazole or rabeprazole, or replacing amoxicillin with metronidazole for people who are allergic to penicillin. In areas with higher rates of clarithromycin resistance, other options are recommended. Such a therapy has revolutionized the treatment of peptic ulcers and has made a cure to the disease possible. Previously, the only option was symptom control using antacids, H2-antagonists or proton pump inhibitors alone.
Antibiotic-resistant disease.
An increasing number of infected individuals are found to harbor antibiotic-resistant bacteria. This results in initial treatment failure and requires additional rounds of antibiotic therapy or alternative strategies, such as a quadruple therapy, which adds a bismuth colloid, such as bismuth subsalicylate. For the treatment of clarithromycin-resistant strains of "H. pylori", the use of levofloxacin as part of the therapy has been suggested.
Ingesting lactic acid bacteria exerts a suppressive effect on "H. pylori" infection in both animals and humans, and supplementing with "Lactobacillus"- and "Bifidobacterium"-containing yogurt improved the rates of eradication of "H. pylori" in humans. Symbiotic butyrate-producing bacteria which are normally present in the intestine are sometimes used as probiotics to help suppress "H. pylori" infections as an adjunct to antibiotic therapy. Butyrate itself is an antimicrobial which destroys the cell envelope of "H. pylori" by inducing regulatory T cell expression (specifically, FOXP3) and synthesis of an antimicrobial peptide called LL-37, which arises through its action as a histone deacetylase inhibitor.
The substance sulforaphane, which occurs in broccoli and cauliflower, has been proposed as a treatment. Periodontal therapy or scaling and root planing has also been suggested as an additional treatment.
Cancers.
Extranodal marginal zone B-cell lymphomas.
Extranodal marginal zone B-cell lymphomas (also termed MALT lymphomas) are generally indolent malignancies. Recommended treatment of "H. pylori"-positive extranodal marginal zone B-cell lymphoma of the stomach, when localized (i.e. Ann Arbor stage I and II), employs one of the antibiotic-proton pump inhibitor regiments listed in the "H. pylori" eradication protocols. If the initial regimen fails to eradicate the pathogen, patients are treated with an alternate protocol. Eradication of the pathogen is successful in 70–95% of cases. Some 50-80% of patients who experience eradication of the pathogen develop within 3–28 months a remission and long-term clinical control of their lymphoma. Radiation therapy to the stomach and surrounding (i.e. peri-gastric) lymph nodes has also been used to successfully treat these localized cases. Patients with non-localized (i.e. systemic Ann Arbor stage III and IV) disease who are free of symptoms have been treated with watchful waiting or, if symptomatic, with the immunotherapy drug, rituximab, (given for 4 weeks) combined with the chemotherapy drug, chlorambucil, for 6–12 months; 58% of these patients attain a 58% progression-free survival rate at 5 years. Frail stage III/IV patients have been successfully treated with rituximab or the chemotherapy drug, cyclophosphamide, alone. Only rare cases of "H. pylori"-positive extranodal marginal zone B-cell lymphoma of the colon have been successfully treated with an antibiotic-proton pump inhibitor regimen; the currently recommended treatments for this disease are surgical resection, endoscopic resection, radiation, chemotherapy, or, more recently, rituximab. In the few reported cases of "H. pylori"-positive extranodal marginal zone B-cell lymphoma of the esophagus, localized disease has been successfully treated with antibiotic-proton pump inhibitor regimens; however, advanced disease appears less responsive or unresponsive to these regimens but partially responsive to rituximab. Antibiotic-proton pump inhibitor eradication therapy and localized radiation therapy have been used successfully to treat H. pylori-positive extranodal marginal zone B-cell lymphomas of the rectum; however radiation therapy has given slightly better results and therefore been suggested to be the disease' preferred treatment. The treatment of localized "H. pylori"-positive extranodal marginal zone B-cell lymphoma of the ocular adenexa with antibiotic/proton pump inhibitor regimens has achieved 2 year and 5 year failure-free survival rates of 67% and 55%, respectively, and a 5 year progression-free rate of 61%. However, the generally recognized treatment of choice for patients with systemic involvement uses various chemotherapy drugs often combined with rituximab.
Diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma is a far more aggressive cancer than extranodal marginal zone B-cell lymphoma. Cases of this malignancy that are "H. pylori"-positive may be derived from the latter lymphoma and are less aggressive as well as more susceptible to treatment than "H. pylori" negative cases. Several recent studies strongly suggest that localized, early-stage diffuse "Helicobacter pylori" positive diffuse large B-cell lymphoma, when limited to the stomach, can be successfully treated with antibiotic-proton pump inhibitor regimens. However, these studies also agree that, given the aggressiveness of diffuse large B-cell lymphoma, patients treated with one of these "H. pylori" eradication regimes need to be carefully followed. If found unresponsive to or clinically worsening on these regimens, these patients should be switched to more conventional therapy such as chemotherapy (e.g. CHOP or a CHOP-like regimen), immunotherapy (e.g. rituximab), surgery, and/or local radiotherapy. "H. pylori" positive diffuse large B-cell lymphoma has been successfully treated with one or a combination of these methods.
Stomach adenocarcinoma.
Helicobacter pylori is linked to the majority of gastric adenocarcinoma cases, particularly those that are located outside of the stomach's cardia (i.e. esophagus-stomach junction). The treatment for this cancer is highly aggressive with even localized disease being treated sequentially with chemotherapy and radiotherapy before surgical resection. Since this cancer, once developed, is independent of "H. pylori" infection, antibiotic-proton pump inhibitor regimens are not used in its treatment.
Prognosis.
"Helicobacter pylori" colonizes the stomach and induces chronic gastritis, a long-lasting inflammation of the stomach. The bacterium persists in the stomach for decades in most people. Most individuals infected by "H. pylori" never experience clinical symptoms, despite having chronic gastritis. About 10–20% of those colonized by "H. pylori" ultimately develop gastric and duodenal ulcers. "H. pylori" infection is also associated with a 1–2% lifetime risk of stomach cancer and a less than 1% risk of gastric MALT lymphoma.
In the absence of treatment, "H. pylori" infection – once established in its gastric niche – is widely believed to persist for life. In the elderly, however, infection likely can disappear as the stomach's mucosa becomes increasingly atrophic and inhospitable to colonization. The proportion of acute infections that persist is not known, but several studies that followed the natural history in populations have reported apparent spontaneous elimination.
Mounting evidence suggests "H. pylori" has an important role in protection from some diseases. The incidence of acid reflux disease, Barrett's esophagus, and esophageal cancer have been rising dramatically at the same time as "H. pylori"s presence decreases. In 1996, Martin J. Blaser advanced the hypothesis that "H. pylori" has a beneficial effect by regulating the acidity of the stomach contents. The hypothesis is not universally accepted as several randomized controlled trials failed to demonstrate worsening of acid reflux disease symptoms following eradication of "H. pylori". Nevertheless, Blaser has reasserted his view that "H. pylori" is a member of the normal flora of the stomach. He postulates that the changes in gastric physiology caused by the loss of "H. pylori" account for the recent increase in incidence of several diseases, including type 2 diabetes, obesity, and asthma. His group has recently shown that "H. pylori" colonization is associated with a lower incidence of childhood asthma.
Epidemiology.
At least half the world's population is infected by the bacterium, making it the most widespread infection in the world. Actual infection rates vary from nation to nation; the developing world has much higher infection rates than the West (Western Europe, North America, Australasia), where rates are estimated to be around 25%.
The age when someone acquires this bacterium seems to influence the pathologic outcome of the infection. People infected at an early age are likely to develop more intense inflammation that may be followed by atrophic gastritis with a higher subsequent risk of gastric ulcer, gastric cancer, or both. Acquisition at an older age brings different gastric changes more likely to lead to duodenal ulcer. Infections are usually acquired in early childhood in all countries. However, the infection rate of children in developing nations is higher than in industrialized nations, probably due to poor sanitary conditions, perhaps combined with lower antibiotics usage for unrelated pathologies. In developed nations, it is currently uncommon to find infected children, but the percentage of infected people increases with age, with about 50% infected for those over the age of 60 compared with around 10% between 18 and 30 years. The higher prevalence among the elderly reflects higher infection rates in the past when the individuals were children rather than more recent infection at a later age of the individual. In the United States, prevalence appears higher in African-American and Hispanic populations, most likely due to socioeconomic factors. The lower rate of infection in the West is largely attributed to higher hygiene standards and widespread use of antibiotics. Despite high rates of infection in certain areas of the world, the overall frequency of "H. pylori" infection is declining. However, antibiotic resistance is appearing in "H. pylori"; many metronidazole- and clarithromycin-resistant strains are found in most parts of the world.
History.
"Helicobacter pylori" migrated out of Africa along with its human host "circa" 60,000 years ago. Recent research states that genetic diversity in "H. pylori", like that of its host, decreases with geographic distance from East Africa. Using the genetic diversity data, researchers have created simulations that indicate the bacteria seem to have spread from East Africa around 58,000 years ago. Their results indicate modern humans were already infected by "H. pylori" before their migrations out of Africa, and it has remained associated with human hosts since that time.
"H. pylori" was first discovered in the stomachs of patients with gastritis and ulcers in 1982 by Drs. Barry Marshall and Robin Warren of Perth, Western Australia. At the time, the conventional thinking was that no bacterium could live in the acid environment of the human stomach. In recognition of their discovery, Marshall and Warren were awarded the 2005 Nobel Prize in Physiology or Medicine.
Before the research of Marshall and Warren, German scientists found spiral-shaped bacteria in the lining of the human stomach in 1875, but they were unable to culture them, and the results were eventually forgotten. The Italian researcher Giulio Bizzozero described similarly shaped bacteria living in the acidic environment of the stomach of dogs in 1893. Professor Walery Jaworski of the Jagiellonian University in Kraków investigated sediments of gastric washings obtained by lavage from humans in 1899. Among some rod-like bacteria, he also found bacteria with a characteristic spiral shape, which he called "Vibrio rugula". He was the first to suggest a possible role of this organism in the pathogenesis of gastric diseases. His work was included in the "Handbook of Gastric Diseases", but it had little impact, as it was written in Polish. Several small studies conducted in the early 20th century demonstrated the presence of curved rods in the stomachs of many people with peptic ulcers and stomach cancers. Interest in the bacteria waned, however, when an American study published in 1954 failed to observe the bacteria in 1180 stomach biopsies.
Interest in understanding the role of bacteria in stomach diseases was rekindled in the 1970s, with the visualization of bacteria in the stomachs of people with gastric ulcers. The bacteria had also been observed in 1979, by Robin Warren, who researched it further with Barry Marshall from 1981. After unsuccessful attempts at culturing the bacteria from the stomach, they finally succeeded in visualizing colonies in 1982, when they unintentionally left their Petri dishes incubating for five days over the Easter weekend. In their original paper, Warren and Marshall contended that most stomach ulcers and gastritis were caused by bacterial infection and not by stress or spicy food, as had been assumed before.
Some skepticism was expressed initially, but within a few years multiple research groups had verified the association of "H. pylori" with gastritis and, to a lesser extent, ulcers. To demonstrate "H. pylori" caused gastritis and was not merely a bystander, Marshall drank a beaker of "H. pylori" culture. He became ill with nausea and vomiting several days later. An endoscopy 10 days after inoculation revealed signs of gastritis and the presence of "H. pylori". These results suggested "H. pylori" was the causative agent. Marshall and Warren went on to demonstrate antibiotics are effective in the treatment of many cases of gastritis. In 1987, the Sydney gastroenterologist Thomas Borody invented the first triple therapy for the treatment of duodenal ulcers. In 1994, the National Institutes of Health stated most recurrent duodenal and gastric ulcers were caused by "H. pylori", and recommended antibiotics be included in the treatment regimen.
The bacterium was initially named "Campylobacter pyloridis", then renamed "C. pylori" in 1987 ("pylori" being the genitive of "pylorus", the circular opening leading from the stomach into the duodenum, from the Ancient Greek word "πυλωρός", which means gatekeeper.). When 16S ribosomal RNA gene sequencing and other research showed in 1989 that the bacterium did not belong in the genus "Campylobacter", it was placed in its own genus, "Helicobacter" from the ancient Greek "έλιξ" ("hělix") "spiral" or "coil".
In October 1987, a group of experts met in Copenhagen to found the European "Helicobacter" Study Group (EHSG), an international multidisciplinary research group and the only institution focused on "H. pylori". The Group is involved with the Annual International Workshop on Helicobacter and Related Bacteria, the Maastricht Consensus Reports (European Consensus on the management of "H. pylori"), and other educational and research projects, including two international long-term projects:
Research.
Results from "in vitro" studies suggest that fatty acids, mainly polyunsaturated fatty acids, have a bactericidal effect against "H. pylori", but their "in vivo" effects have not been proven.